Non-Hodgkin Lymphoma

Sonrotoclax (BGB-11417) in Relapsed or Refractory Mantle Cell Lymphoma: Early Findings From a Phase I/II Study

Sonrotoclax (BGB-11417) is a next generation, highly selective B-cell lymphoma 2 (BCL-2) inhibitor under investigation for patients with relapsed or refractory mantle cell lymphoma (R/R...

Latest Posts

Mosunetuzumab Expands Promise in Mantle Cell and Marginal Zone Lymphoma: Phase II Results

Mosunetuzumab showed early promise for improving outcomes in two key lymphoma subtypes with 88% response...

Circulating Tumor DNA Outperforms PET Imaging for Minimal Residual Disease Detection in Large B-Cell Lymphoma

ctDNA detection after LBCL therapy predicts 97% vs 29% progression-free survival, superior to PET scans...

POLARGO Trial: Polatuzumab Vedotin Improves Survival in Relapsed/Refractory DLBCL

40% reduction in death risk with Pola-R-GemOx vs R-GemOx alone in relapsed/refractory DLBCL (HR 0.60,...

Hematologic Malignancies Insight Center

Multiple Myeloma (MM)

Acute Lymphoblastic Leukemia (ALL)

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest